MERCK PHARMA R&D
One of 10,000+ projects Taiyo tracks in Germany.
Source: European Investment Bank (EIB)
The project will finance the promoter’s research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications.
- Status
- Under Construction
- Sector
- Government
- Location
- Germany
- Updated
- 22 Jul 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about MERCK PHARMA R&D
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | signed |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The project will finance the promoter’s research and development (R&D) expenses for the development of a new cancer treatment. It concerns the clinical programme of a cancer vaccine for indications such as NSCLC (non-small-cell lung cancer), which is the major indication currently investigated, as well as trials for colorectal- , prostate- and breast cancer indications. |
Original sector | Industry |
Location
Country | Germany |
Source
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Government |
Article published date | 2025-07-28 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
